Eledon
2 known investors
Eledon develops tegoprubart, an anti-CD40L antibody in clinical development for preventing rejection in organ transplant recipients. The company focuses on improving long-term graft survival and quality of life for transplant recipients across kidney, liver, and xenotransplantation.
Founders & leadership
SP
Steven PerrinPresident and Chief Scientific Officer